APA

Para M. F., Meehan P., Holden-Wiltse J., Fischl M., Morse G., Shafer R., Demeter L. M., Wood K., Nevin T., Virani-Ketter N. & Freimuth W. W. (19990623). ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. : Antimicrobial agents and chemotherapy.

Chicago

Para M F, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter L M, Wood K, Nevin T, Virani-Ketter N and Freimuth W W. 19990623. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. : Antimicrobial agents and chemotherapy.

Harvard

Para M. F., Meehan P., Holden-Wiltse J., Fischl M., Morse G., Shafer R., Demeter L. M., Wood K., Nevin T., Virani-Ketter N. and Freimuth W. W. (19990623). ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. : Antimicrobial agents and chemotherapy.

MLA

Para M F, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter L M, Wood K, Nevin T, Virani-Ketter N and Freimuth W W. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. : Antimicrobial agents and chemotherapy. 19990623.